How merging AI-driven molecular discovery with nuclear medicine manufacturing could accelerate radiopharmaceutical innovation and clinical translation.
Key Takeaways
- Sanyou Bio and Baiyunshan Xihe signed a strategic cooperation to co-develop radiopharmaceuticals
- Sanyou will provide AI-STAL and SAI-DA platforms for antibody and targeting molecule discovery
- They will jointly develop theranostic agents labeled with Gallium-68